At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
HIL-214biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Single-arm, Open-label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular HIL-214 Norovirus Vaccine in Adults Aged 18 to 49 Years
In Brief
A Phase 2 clinical trial evaluating HIL-214 for Gastroenteritis. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
The purpose of this trial is to obtain serum for proficiency testing to confirm assay validity is maintained following the dosing of adults with a pediatric dose of HIL-214.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroenteritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartAug 2023
First PostedAug 2023
Primary CompletionAug 2023
Study CompletionNov 2023
TodayJul 2026
First PostedAug 2, 2023
Enrollment StartAug 1, 2023
Primary CompletionAug 14, 2023
Study CompletionNov 10, 2023
TodayJul 2, 2026
Enrollment to primary: 13 daysPosted 2.9 years ago
Interventions
HIL-214biological
HIL-214